Among all breast cancers, the subtype triple-negative breast cancer (TNBC) makes up 15 to 20%, which is defined as estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and human epidermal growth factor receptor-2 (HER-2)-negative [2]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.